JP2006518743A5 - - Google Patents

Download PDF

Info

Publication number
JP2006518743A5
JP2006518743A5 JP2006503721A JP2006503721A JP2006518743A5 JP 2006518743 A5 JP2006518743 A5 JP 2006518743A5 JP 2006503721 A JP2006503721 A JP 2006503721A JP 2006503721 A JP2006503721 A JP 2006503721A JP 2006518743 A5 JP2006518743 A5 JP 2006518743A5
Authority
JP
Japan
Prior art keywords
solution
emulsion
cancer
dihydrosphingosine
sphingolipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006503721A
Other languages
English (en)
Japanese (ja)
Other versions
JP4842800B2 (ja
JP2006518743A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/004960 external-priority patent/WO2004075834A2/en
Publication of JP2006518743A publication Critical patent/JP2006518743A/ja
Publication of JP2006518743A5 publication Critical patent/JP2006518743A5/ja
Application granted granted Critical
Publication of JP4842800B2 publication Critical patent/JP4842800B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006503721A 2003-02-21 2004-02-19 サフィンゴールの医薬組成物およびその使用方法 Expired - Fee Related JP4842800B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44953603P 2003-02-21 2003-02-21
US60/449,536 2003-02-21
PCT/US2004/004960 WO2004075834A2 (en) 2003-02-21 2004-02-19 Stabilized pharmaceutical compositions of safingol and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010290577A Division JP2011126886A (ja) 2003-02-21 2010-12-27 サフィンゴールの医薬組成物およびその使用方法

Publications (3)

Publication Number Publication Date
JP2006518743A JP2006518743A (ja) 2006-08-17
JP2006518743A5 true JP2006518743A5 (cg-RX-API-DMAC10.html) 2007-04-05
JP4842800B2 JP4842800B2 (ja) 2011-12-21

Family

ID=32927531

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006503721A Expired - Fee Related JP4842800B2 (ja) 2003-02-21 2004-02-19 サフィンゴールの医薬組成物およびその使用方法
JP2010290577A Withdrawn JP2011126886A (ja) 2003-02-21 2010-12-27 サフィンゴールの医薬組成物およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010290577A Withdrawn JP2011126886A (ja) 2003-02-21 2010-12-27 サフィンゴールの医薬組成物およびその使用方法

Country Status (9)

Country Link
US (1) US7476692B2 (cg-RX-API-DMAC10.html)
EP (1) EP1594488B1 (cg-RX-API-DMAC10.html)
JP (2) JP4842800B2 (cg-RX-API-DMAC10.html)
AT (1) ATE331507T1 (cg-RX-API-DMAC10.html)
CA (1) CA2516399C (cg-RX-API-DMAC10.html)
DE (1) DE602004001393T2 (cg-RX-API-DMAC10.html)
ES (1) ES2270347T3 (cg-RX-API-DMAC10.html)
MX (1) MXPA05008860A (cg-RX-API-DMAC10.html)
WO (1) WO2004075834A2 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2013016B8 (en) 2006-03-29 2014-10-08 Wayne State University Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery
CA2817198C (en) * 2009-11-12 2018-05-01 Texas Tech University Compositions and methods for treating hyperproliferative disorders
WO2015013566A1 (en) * 2013-07-25 2015-01-29 Nemucore Medical Innovations, Inc. Nanoemulsions of hydrophobic platinum derivative
IT201600105201A1 (it) * 2016-10-19 2018-04-19 Nutrilinea Srl Uso della fosfatidilserina per la prevenzione e il trattamento dei disturbi della prostata e relative composizioni farmaceutiche e nutraceutiche
US10034895B2 (en) * 2017-11-30 2018-07-31 Joel Steven Goldberg Local application of D-lactic acid dimer is selectively cytotoxic when applied to cancer cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0716589A4 (en) * 1993-07-23 1997-06-11 Morris Herstein COSMETIC COMPOSITION STIMULATING THE RENEWAL OF THE SKIN WITH A PROLONGED IRRITATION ELIMINATION EFFECT
CA2234968A1 (en) * 1995-10-18 1997-04-24 Mary Kay Inc. Topically applied, structural cellulite treatments
US5635536A (en) 1994-12-07 1997-06-03 Pharmacia & Upjohn Aktiebolag Emulsion suitable for administering a sphingolipid
US6368831B1 (en) * 1998-06-29 2002-04-09 Childrens Hospital Los Angeles Treatment of hyperproliferative disorders
US6352844B1 (en) * 1998-06-29 2002-03-05 Childrens Hospital Los Angeles Treatment of hyperproliferative disorders
JP3220434B2 (ja) 1998-12-28 2001-10-22 花王株式会社 化粧料
KR100343885B1 (ko) * 1999-07-20 2002-07-19 주식회사 두산 파이토스핑고신의 수용액의 제조 방법
KR100371491B1 (ko) * 1999-07-27 2003-02-07 주식회사 두산 피부 보호용 크림조성물
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
JP3896234B2 (ja) * 1999-12-24 2007-03-22 花王株式会社 化粧料
EP1287815A1 (en) * 2001-08-31 2003-03-05 Cosmoferm B.V. Use of a sphingoid base for inhibiting ceramidase activity
US7846969B2 (en) 2001-12-10 2010-12-07 Kao Corporation Ceramide emulsions
JP4119646B2 (ja) * 2001-12-10 2008-07-16 花王株式会社 セラミド類乳化物の製造法
JP4220698B2 (ja) * 2001-12-10 2009-02-04 花王株式会社 皮膚外用剤
JP2005538156A (ja) * 2002-09-05 2005-12-15 ガルデルマ・ソシエテ・アノニム 爪塗布用溶液

Similar Documents

Publication Publication Date Title
JP6392209B2 (ja) 粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア
US20090047336A1 (en) novel formulation of dehydrated lipid vesicles for controlled release of active pharmaceutical ingredient via inhalation
JP2006502233A (ja) 白金凝集物およびその製造方法
JP2021152032A (ja) トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
KR20170132152A (ko) 나노입자를 이용한 종양 치료 조성물 및 방법
ES2770113T3 (es) Análogos de la cisteamina resistentes a la ADO y sus usos
RU2013105783A (ru) Парентеральные составы производных элацитарабина
BRPI0510778B1 (pt) Composição farmacêutica, processo para preparação da :mesma, e, uso de uma composição
AU2005284909B2 (en) Delivering iron to an animal
CN116688137B (zh) 一种基于核壳结构的药物组合物及应用
KR100313149B1 (ko) 셀레질린을함유하는리포솜조성물
JP2011126886A (ja) サフィンゴールの医薬組成物およびその使用方法
JP2024526791A (ja) リポソーム製剤の調製方法
WO2025012723A1 (en) Liposome encapsulated apomorphine
JP2015209417A (ja) 経口疾患治療薬
JPH10265383A (ja) 医薬組成物
JPH01175944A (ja) 虚血性疾患予防及び治療剤
CN113786387B (zh) 一种石杉碱甲脂质体及其在治疗阿尔兹海默症药物中的应用
US20230144385A1 (en) Ethanolamine formulation for treating epithelial ovarian carcinoma
WO2007006232A1 (fr) Complexe de phospholipide et d’acide hyaluronique et procédé de préparation
JP2000302685A (ja) 抗腫瘍薬含有リポソーム製剤
Musheer et al. Formulation, Development and Characterization of Effective Niosomal Drug Delivery System for the Treatment of Diabetes Mellitus
WO2023190709A1 (ja) リポソーム組成物およびリポソームを含む医薬組成物
CN117582408A (zh) 一种雾化吸入用纳米脂质体及其制备方法和应用
BR102017021294A2 (pt) Processo de obtenção de carreadores lipídicos nanoestruturados, carreadores lipídicos nanoestruturados obtidos e uso dos mesmos